Emerging therapies include sodium-glucose cotransporter 2 (SGLT2) inhibitors, which exhibit antiinflammatory and antifibrotic effects in preclinical models (56), and clinical data suggest cardioprotective potential in anthracycline-treated patients, with HF hospitalizations decreased by 51% and HF diagnoses reduced by 71% (57, 58). This evidence concerns the gene SLC5A2 and hydrops fetalis.